BioSpace News Archive

Intranasal Oxytocin with Magnesium Demonstrated Augmented Craniofacial Analgesia in an Animal Model Enhanced Effect of Mg 2+ is the Core Patented Technology of TNX-1900 for Migraine.

EyePoint Pharmaceuticals, Inc. today announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

PetVivo Holdings, Inc., an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for companion animals, will report financial results for the year ending March 31, 2022, on Wednesday, June 29, 2022 after market close.

Ocugen’s partner Bharat Biotech’s Phase 2/3 study of COVAXIN™ (BBV152) in 526 children showed safety, efficacy, and superior response to that shown in adults.

DERMALA Inc., a science-based consumer dermatology company developing novel, microbiome-based solutions for chronic skin conditions, announced today the issuance of the U.S. Patent No. 11,364,214 - COMPOSITIONS AND METHODS FOR TREATING ECZEMA.

Ms. Quigley’s Broad Biotechnology Industry Experience Encompasses Leadership Positions in Executive Management, Operations and Legal Affairs.

Preclinical data show synergistic protective effect of anti-protein and anti-polysaccharide antibodies in a highly virulent model of serotype 3 invasive pneumococcal disease.

Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN).

Bruker is Ushering in the Age of Spatial Single-Cell Metabolomics.

GC 2400 solution streamlines performance and delivers superior precision for high throughput environments.